Literature DB >> 30981840

Monoallelic expression of the TTR gene as a contributor to the age at onset and penetrance of TTR-related amyloidosis.

Iglika Yordanova1, Zornitza Pavlova2, Andrey Kirov3, Tihomir Todorov1, Assen Alexiev4, Stayko Sarafov5, Lyudmila Mateva4, Teodora Chamova5, Mariana Gospodinova6, Vanyo Mitev7, Ivailo Tournev8, Albena Todorova9.   

Abstract

TTR-related amyloidosis (ATTR) is manifested in two allelic forms: familial amyloid polyneuropathy (TTR-FAP) and cardiomyopathy (TTR-FAC), both caused by mutations in the TTR gene. The most prevalent mutation in Bulgaria is p.Glu89Gln. Markedly different age at onset and disease penetrance is noticed in Bulgarian p.Glu89Gln cases even in a single family or between genetically identical twins. The present study aimed to evaluate the transcription profile of the TTR gene in order to better understand the difference in disease onset and penetrance. Six p.Glu89Gln positive families were selected from our registry, based on intrafamilial differences in disease onset and penetrance. Plasma and urine specimens were collected from 13 patients and subjected to transcription analysis. Both mutant and wild type transcripts were visualized in a mixed transcription profile, which is the traditional model of autosomal gene expression. The results from a relative quantification of the mutant versus wild type transcript showed presence of the mutant transcript between 0.14 and 1.14 times against the wild type. In addition, monoallelic expression signature was also detected. Based on our results we propose a model of natural selection, which includes age-related allele exclusion or suppression: predominant expression of a wild type (at an early age) and mutant (at the process of ageing) alleles. The intrafamilial differences in disease onset and penetrance need to be considered in genetic counselling and in follow-up of mutation carriers.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  ATTR; FAP; Monoallelic expression; Penetrance; TTR gene

Mesh:

Substances:

Year:  2019        PMID: 30981840     DOI: 10.1016/j.gene.2019.04.030

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  2 in total

1.  Seven Years of Selective Genetic Screening Program and Follow-Up of Asymptomatic Carriers With Hereditary Transthyretin Amyloidosis in Bulgaria.

Authors:  Teodora Chamova; Mariana Gospodinova; Ognian Asenov; Tihomir Todorov; Zornitsa Pavlova; Andrey Kirov; Sylvia Cherninkova; Kristina Kastreva; Ani Taneva; Stanislava Blagoeva; Sashka Zhelyazkova; Plamen Antimov; Kaloian Chobanov; Albena Todorova; Ivailo Tournev
Journal:  Front Neurol       Date:  2022-04-08       Impact factor: 4.003

2.  Amyloidogenicity assessment of transthyretin gene variants.

Authors:  Nicolai B Grether; Felix Napravnik; Thomas Imhof; Reinhold P Linke; Jan H Bräsen; Jessica Schmitz; Maike Dohrn; Christian Schneider; Martin K R Svačina; Jörg Stetefeld; Manuel Koch; Helmar C Lehmann
Journal:  Ann Clin Transl Neurol       Date:  2022-07-29       Impact factor: 5.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.